Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
228.4 BRL | -10.24% | +4.08% | -8.58% |
01:37pm | ABL Bio, BMS Collaborate on Gastric Cancer Treatment Trial | MT |
06-07 | Geron shares surge after U.S. FDA approves blood disorder drug | RE |
Sales 2024 * | 46.09B 247B 63.4B | Sales 2025 * | 46.06B 247B 63.36B | Capitalization | 86.29B 462B 119B |
---|---|---|---|---|---|
Net income 2024 * | -5.41B -28.99B -7.45B | Net income 2025 * | 10.22B 54.73B 14.06B | EV / Sales 2024 * | 2.72 x |
Net Debt 2024 * | 39.03B 209B 53.7B | Net Debt 2025 * | 31.68B 170B 43.57B | EV / Sales 2025 * | 2.56 x |
P/E ratio 2024 * |
-15.8
x | P/E ratio 2025 * |
7.85
x | Employees | 34,100 |
Yield 2024 * |
5.8% | Yield 2025 * |
6.09% | Free-Float | 69.27% |
Latest transcript on Bristol-Myers Squibb Company
1 day | -10.24% | ||
1 week | +4.08% | ||
Current month | +8.79% | ||
1 month | -0.57% | ||
3 months | -15.05% | ||
6 months | -8.53% | ||
Current year | -8.58% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 53 | 15-01-31 | |
David Elkins
DFI | Director of Finance/CFO | 55 | 19-11-19 |
Greg Meyers
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Phyllis Yale
BRD | Director/Board Member | 66 | 19-11-19 |
Peter Arduini
BRD | Director/Board Member | 59 | 16-03-31 |
Derica Rice
BRD | Director/Board Member | 59 | 20-08-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-06-10 | 228.4 | -10.24% | 1 227 |
24-06-04 | 220.8 | +0.57% | 134 |
24-06-03 | 219.5 | +4.52% | 5 |
Delayed Quote Sao Paulo, June 10, 2024 at 03:52 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+48.39% | 765B | |
-6.13% | 354B | |
+20.61% | 331B | |
+10.00% | 299B | |
+18.87% | 248B | |
-1.96% | 219B | |
+11.11% | 216B | |
+5.80% | 164B | |
-2.50% | 162B |
- Stock Market
- Equities
- BMY Stock
- BMYB34 Stock